Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This diagnostics company's stock is on fire in 2020 due to its coronavirus tests.

Why Co-Diagnostics Stock Soared 59% in May

Great Lakes Dredge & Dock

RCI Hospitality

Sportsman's Warehouse Hlds

A mind-boggling 2.5 million were employed in May, in contrast to several economists' apprehensions of a loss of 7.25 million jobs. Here's how to play May's surprising jobs gain -

Here's How to Play May's Stunning Jobs Report

The price target for CODX stock has been raised, but the testing-kit leader should easily clear the bar. More upside ahead.

Co-Diagnostics Stock Will Meet High Analyst Expectations

The rush to develop a COVID-19 diagnostic test has pushed CODX stock to new highs. But investors may need more scientific evidence to stay in the shares long-term.

It May Be Time to Take Profits in Co-Diagnostics Stock

Alexco Resource

Geron

Top Ranked Momentum Stocks to Buy for June 5th

Top Ranked Momentum Stocks to Buy for June 5th 2020

CODX stock could continue delivering upside if its novel coronavirus test kit proves accurate and vaccines take awhile to come to market.
The post Co-Diagnostics Could Be a Prudent Coronavirus Play appeared first on InvestorPlace.

Co-Diagnostics Could Be a Prudent Coronavirus Play

From an investment standpoint, I’m always thinking about my options. I don’t necessarily have to invest in CODX stock because there are other potential options available, ones probably safer in the grand scheme of things.

Make This Biotech Play if You Like Co-Diagnostics’ Chances

The fear of missing out is a real stock price driver. Add to it the fear of the virus and you get unlimited upside potential for CODX stock.

Co-Diagnostics Stock Is Up 1,800%, So Bet on the Next Burst

B&G Foods

Mersana Therapeutics

Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener

Co-Diagnostics: Why Traders Shouldn't Take COVID-19 Stocks Too Seriously

There's evidence that Co-Diagnostics' test is not as accurate as many of its competitors' offerings. That makes CODX stock quite risky.

Co-Diagnostics Stock Will Be Weighed Down by Multiple Issues

Co-Diagnostics may be worth much more than today's price. CODX stock could be worth two or three times more, under certain estimates.

Co-Diagnostics Could Soar With Its Coronavirus Test

SALT LAKE CITY, May 27, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Company CEO Dwight Egan has been invited to present at The Role of Cell Therapy...

Co-Diagnostics, Inc. to Present at COVID-19 Virtual Conference Hosted by Maxim Group on May 27, 2020

Co-Diagnostics benefits from the quantity and quality of its test kits. This means CODX stock should long be one of investors' favorites.

Co-Diagnostics’ Test Kits Still Make CODX Stock a Great Buy

Co-Diagnostics (CODX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Co-Diagnostics (CODX): Strong Industry, Solid Earnings Estimate Revisions

SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the publication of a paper showing its Logix Smart™ COVID-19 Test Kit was used to...

Co-Diagnostics, Inc. COVID-19 Test Successfully Used to Identify Coronavirus in Cancer Tissue

As of late, it has definitely been a great time to be an investor in Co-Diagnostics.

Co-Diagnostics' Shares March Higher, Can It Continue?

Alibaba

Humana

iBio

Moderna

Block

We're starting to see some light at the end of the coronavirus tunnel, and investors are looking at stocks to buy for a post-crisis bump.

6 Top-Rated Stocks for a Post-Coronavirus-Crisis Bump

CoDiagnostics, Inc. (CODX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can CoDiagnostics, Inc. (CODX) Run Higher on Rising Earnings Estimates?

CoDiagnostics, Inc. (CODX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

CoDiagnostics, Inc. (CODX) Moves to Strong Buy: Rationale Behind the Upgrade

For the molecular diagnostics company to earn such a big boost in its valuation, sales of its COVID-19 test will need to grow at an ambitious rate.

Will Co-Diagnostics Stock Go to $30?

It claims its Logix antibody test is 100% accurate, and investors have bid its stock up in consequence. However, even a 2% rate of false positives could be a huge problem for the test and the stock.

Is Co-Diagnostics' Stock in a Bubble?

Co-Diagnostics has seen its business explode because of the coronavirus pandemic and CODX stock is up over 1800% so far in 2020.
The post Co-Diagnostics Stock Positioned for Continued Growth in 2020 appeared first on InvestorPlace.

Co-Diagnostics Stock Positioned for Continued Growth in 2020

The last thing you need in your portfolio is a drastically volatile asset. Avoid CODX stock in both short- and long-term trades.

Stop the Insanity with Co-Diagnostics Stock Already

Investors need to pay close attention to Co-Diagnostics (CODX) stock based on the movements in the options market lately.

News for Co-Diagnostics Stock (CODX)